Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Japan Economy Poised for Q4 2025 Growth as Investment and Consumption Hold Firm 
Global Markets Slide as AI, Crypto, and Precious Metals Face Heightened Volatility 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
Bank of Japan Signals Readiness for Near-Term Rate Hike as Inflation Nears Target 
Asian Markets Surge as Japan Election, Fed Rate Cut Bets, and Tech Rally Lift Global Sentiment 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Oil Prices Slip as U.S.-Iran Talks Ease Middle East Tensions 
Lotte Group is set to acquire a bioindustry CMO plant located in the United States. The move has been announced on Thursday, May 5, and this also signals the company’s entrance into the bio business.
Currently, the acquisition process for the contract manufacturing organization (CMO) facility is still ongoing. Investment banking industry insiders said that Lotte Group has taken this step to buy the CMO plant after it stated that the bioindustry will be its new growth engine.
According to The Korea Times, CMOs are firms that specialize in the production of biopharmaceuticals that were developed by other companies. Lotte Group’s new CMO business will be headed by Lee Won Jik, a former executive at Samsung Biologics that the company recently hired. He has been tasked to develop and grow this business unit that the Lotte Group set up.
Lee will also be leading the acquisition efforts of the CMO as per the report. It was only last month when the South Korean multinational conglomerate declared during its general shareholders' meeting that its next growth engine for the future will be the bioindustry. Lotte Holdings will be investing directly in this business and will provide support to help it grow and succeed.
Meanwhile, as part of its entrance into the CMO business, Lotte Group applied for a trademark for its new biz. The company registered “Lotte Biologics” with the Korean Intellectual Property Office (KIPO) to officially launch its bio venture.
It was added that under the new Lotte Biologics banner, Lotte will also be participating in the largest bioindustry expo in the world called the Bio International Convention (Bio USA) which is set to take place next month in San Diego, California.
KIPO revealed that Lotte Holdings applied for the patent last week and aside from the name, it also trademarked some business areas such as customized manufacturing of biopharmaceuticals and drug processing and medical diagnostic devices for virus testing, The Korea Herald reported.
“Registering the trademark of Lotte Biologics was a part of preparations for the group’s bio business,” an official of Lotte Holdings stated. “We are reviewing various ways to enter the bio industry, but nothing has been confirmed at the moment.”
